PALO ALTO, Calif. - Semnur Pharmaceuticals, Inc., a subsidiary of Scilex Holding Company (NASDAQ: SCLX), and Denali Capital Acquisition Corp. (NASDAQ: DECA) announced their intent to merge in a deal that could value Semnur at up to $2 billion. This business combination aims to create a publicly traded biopharmaceutical entity focused on the development of non-opioid pain management therapies.
The centerpiece of the merger is Semnur's lead product, SP-102 (SEMDEXA™), a non-opioid injectable gel for the treatment of sciatica, which is currently in Phase 3 clinical trials and has been granted Fast Track status by the FDA. The anticipated proceeds from the transaction are expected to fund the final Phase 3 study of SP-102 and potential New Drug Application filing with the FDA.
Scilex is set to be the majority stakeholder in the new entity post-merger. Additionally, Scilex's board has approved a resolution to potentially distribute up to 10% of its ownership interest in Semnur as a dividend in connection with the merger, subject to SEC registration requirements.
The proposed combination is contingent on the negotiation of a definitive merger agreement, approval by both companies' boards, and SPAC shareholder approval. While the letter of intent outlines the structure and terms of the proposed transaction, these are subject to change.
Semnur's SP-102 (SEMDEXA™) represents a significant advancement in the treatment of sciatica, a condition with no FDA-approved therapies. Previous Phase 3 trials have shown the treatment to be effective in reducing pain and disability in patients with sciatica, with safety comparable to placebo. Independent market research by Syneos Health (NASDAQ:SYNH) Consulting suggests SP-102 could reach peak sales of up to $3.6 billion annually within five years of its launch.
The merger is part of a broader industry trend towards developing alternatives to opioids, which currently account for a significant portion of the chronic pain management market but are associated with risks of abuse and misuse.
This announcement is based on a press release statement and does not constitute financial advice or an endorsement of the proposed transaction. The completion of the deal remains uncertain and subject to various approvals and conditions.
In other recent news, Denali Capital Acquisition Corp. has terminated its merger agreement with Longevity Biomedical. This decision was mutual and both parties have parted ways without further obligations to proceed with the combination. In light of these recent developments, Denali's management is now actively exploring alternative opportunities to execute an initial business combination.
Denali Capital Acquisition Corp., often known as a blank check company, was established with the intent of merging with or acquiring a business or businesses. The termination of the merger agreement with Longevity Biomedical marks a shift in Denali's strategy as it seeks to fulfill its purpose through a different transaction. The company has not yet provided details on potential new merger targets or the timeline for announcing a new business combination.
Denali's initial public offering prospectus highlighted various risk factors that could influence its business plans, including changes in market conditions and the regulatory environment.
The company has made it clear that forward-looking statements regarding its business prospects are subject to numerous conditions and uncertainties. As these recent events unfold, the company's future moves are eagerly anticipated as it reassesses its options for a merger or acquisition that aligns with its investment criteria.
InvestingPro Insights
As Denali Capital Acquisition Corp. (DECA) navigates the potential merger with Semnur Pharmaceuticals, investors are closely monitoring the financial metrics and market performance of DECA. According to InvestingPro data, DECA has seen a remarkable 87.62% return over the last month, which could be indicative of investor optimism surrounding the merger's prospects and the future of non-opioid pain management therapies.
Despite the recent surge in price, DECA is trading at a P/E ratio of 52.87, which might seem high; however, when adjusted for the last twelve months as of Q1 2024, the P/E ratio appears more favorable at 42.34. This could suggest that investors are willing to pay a premium for DECA's growth potential, especially considering the company's significant short-term returns and the potential market for SP-102.
Additionally, the InvestingPro Fair Value estimate for DECA stands at $5.75, which may provide a reference point for investors weighing the company's current trading price against its estimated intrinsic value. With the InvestingPro platform offering additional insights, there are 9 more InvestingPro Tips available for DECA, which can be accessed at https://www.investing.com/pro/DECA. For those interested in a deeper analysis, use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
The financial data and market performance of DECA are crucial for stakeholders considering the impact of the merger on their investment. With the company showing strong returns over various periods and a favorable P/E ratio when adjusted for near-term earnings growth, the merger proposal adds a layer of potential value for both companies involved.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.